Clinical Trial Detail

NCT ID NCT02296242
Title Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors BioMed Valley Discoveries, Inc
Indications

acute myeloid leukemia

bone marrow cancer

Therapies

Ulixertinib

Age Groups: adult

Additional content available in CKB BOOST